Cargando…
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy
BACKGROUND: Pancreatic adenocarcinoma (PAAD) is an aggressive solid tumour characterised by few early symptoms, high mortality, and lack of effective treatment. Therefore, it is important to identify new potential therapeutic targets and prognostic biomarkers of PAAD. METHODS: The Cancer Genome Atla...
Autores principales: | Du, Xingyi, Yi, Xiaoyu, Zou, Xiaocui, Chen, Yuan, Tai, Yanhong, Ren, Xuhong, He, Xinhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642060/ https://www.ncbi.nlm.nih.gov/pubmed/37957639 http://dx.doi.org/10.1186/s12885-023-11474-1 |
Ejemplares similares
-
High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma
por: Curia, Maria Cristina, et al.
Publicado: (2019) -
Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma
por: Guan, Shasha, et al.
Publicado: (2022) -
GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma
por: Liu, Bo, et al.
Publicado: (2021) -
Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients
por: Bing, Yuntao, et al.
Publicado: (2018) -
Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer
por: Liu, Wentao, et al.
Publicado: (2018)